Inhibition of TGF-beta-induced collagen accumulation in rat NRK-49F cells at 10 uM incubated for 2 days by PSR staining based microscopic analysis relative to control
Antimigratory activity in mouse L929 cells assessed as inhibition of TGF-beta-induced cell migration at 10 uM incubated for 24 hrs by wound healing assay
Inhibition of TGF-beta induced SMAD2 phosphorylation in rat NRK-49F cells at 20 to 40 uM pretreated with compound for 1 to 2 hrs followed by TGF-beta stimulation for 1 hr by Western blot analysis
Inhibition of TGF-beta induced SMAD3 phosphorylation in rat NRK-49F cells at 20 to 40 uM pretreated with compound for 1 to 2 hrs followed by TGF-beta stimulation for 1 hr by Western blot analysis
Inhibition of TGF-beta induced ERK1/2 phosphorylation in rat NRK-49F cells at 20 to 40 uM pretreated with compound for 1 to 2 hrs followed by TGF-beta stimulation for 1 hr by Western blot analysis
Inhibition of TGF-beta induced p38 phosphorylation in rat NRK-49F cells at 20 to 40 uM pretreated with compound for 1 to 2 hrs followed by TGF-beta stimulation for 1 hr by Western blot analysis
Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as reduction in collagen deposition by measuring hydroxyproline content in lung at 50 to 100 mg/kg, po administered for 30 days starting from day 1 post bleomycin treatment
Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as reduction in collagen deposition by measuring hydroxyproline content in lung at 100 mg/kg, po administered for 21 days starting from day 8 post bleomycin treatment
Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as survival rate at 50 to 100 mg/kg, po administered for 30 days starting from day 1 post bleomycin treatment
Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as survival rate at 50 mg/kg, po administered for 21 days starting from day 8 post bleomycin treatment